<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02056782</url>
  </required_header>
  <id_info>
    <org_study_id>PGX-ODSH-2013-AML-1</org_study_id>
    <nct_id>NCT02056782</nct_id>
  </id_info>
  <brief_title>A Pilot Study of ODSH in Acute Myeloid Leukemia</brief_title>
  <acronym>PGX-AML</acronym>
  <official_title>A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cantex Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Translational Drug Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cantex Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Pilot Study of ODSH in Acute Myeloid Leukemia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multi-center, 10 patient pilot study with an anticipated 1 year
      enrollment period

      Primary Objectives:

        1. To evaluate the safety and tolerability of ODSH in patients with Acute Myeloid Leukemia
           (AML) receiving cytarabine and idarubicin induction or cytarabine consolidation
           chemotherapy.

        2. To determine whether there is preliminary evidence of an effect of ODSH on time to
           transfusion-independent platelet recovery in Acute Myeloid Leukemia (AML) patients
           receiving cytarabine and idarubicin induction or cytarabine consolidation chemotherapy.

      Secondary Objectives:

        1. To determine whether there is preliminary evidence of an effect of ODSH on remission
           rate following cytarabine and idarubicin induction in Acute Myeloid Leukemia (AML)
           patients.

        2. To determine whether there is preliminary evidence of an effect of ODSH on improving
           platelet nadir counts in Acute Myeloid Leukemia (AML) patients receiving cytarabine and
           idarubicin induction or cytarabine consolidation chemotherapy.

        3. To determine whether there is preliminary evidence of an effect of ODSH on decreasing
           the number of platelet transfusions in Acute Myeloid Leukemia (AML) patients receiving
           cytarabine and idarubicin induction or cytarabine consolidation chemotherapy.

        4. To determine whether there is preliminary evidence of an effect of ODSH on reducing
           overall side effects of chemotherapy in Acute Myeloid Leukemia (AML) patients receiving
           cytarabine and idarubicin induction or cytarabine consolidation chemotherapy.

      Enrollment for newly diagnosed, previously untreated acute myeloid leukemia. Acute
      promyelocytic leukemia and acute megakaryoblastic leukemia subtypes are excluded.

      All patients will receive standard induction chemotherapy with cytarabine 100 mg/m2/day by
      continuous intravenous infusion over 24 hours daily for 7 days (D 1-7) plus idarubicin 12
      mg/m2/day by intravenous injection daily for 3 days (D 1-3). For consolidation, patients
      younger than 60 will receive cytarabine at a dose of 3 grams/m2 over 3 hours, every 12 hours
      on days 1, 3, and 5.

      Induction cycle: ODSH 4 mg/kg IV bolus day 1, 30 minutes after completion of administration
      of the first dose of idarubicin, then ODSH 0.25 mg/kg/hour for 24 hours daily by continuous
      IV infusion days 1-7.

      Consolidation cycle: ODSH 4 mg/kg IV bolus day 1 administered 30 minutes after completion of
      infusion of the first dose of cytarabine then ODSH 0.25 mg/kg/hour for 24 hours daily by
      continuous IV infusion days 1-5

      7 days in induction cycle and 5 days in consolidation cycles
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of ODSH in patients with Acute Myeloid Leukemia (AML) receiving cytarabine and idarubicin induction or cytarabine consolidation chemotherapy</measure>
    <time_frame>Outcome measured daily, for change, in the first 35 days</time_frame>
    <description>The primary endpoint is the safety and tolerability of ODSH in patients with Acute Myeloid Leukemia (AML) receiving cytarabine and idarubicin induction and cytarabine consolidation chemotherapy. Safety events will be tabulated and reported by type of adverse event and grade. Primary endpoints will be evaluated using descriptive statistics</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>PGX-ODSH-2013-AML-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Intervention Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PGX-ODSH-2013-AML-1</intervention_name>
    <description>Eligible patients will receive idarubicin at 12 mg/m2 days 1-3 of induction plus a seven-day continuous infusion of cytarabine at 100 mg/m2/day days 1-7 of induction. For consolidation, patients younger than 60 will receive cytarabine at 3 grams/m2 over 3 hours every 12 hours days 1, 3, and 5 of the cycle. Patients over 60 will come off study following induction.
In induction, ODSH will be administered as a 4 mg/kg bolus 30 minutes after the first idarubicin dose followed immediately by a continuous intravenous ODSH infusion of 0.25 mg/kg/hour for 24 hours daily for seven consecutive days (days 1-7) for a total of 168 hours of continuous ODSH infusion.
In consolidation, ODSH will be administered as a 4 mg/kg bolus 30 minutes after completion of the first 3-hour infusion of cytarabine, followed immediately by a continuous ODSH intravenous infusion of 0.25 mg/kg/hour for 24 hours daily for five consecutive days (days 1-5) for a total of 120 hours of continuous ODSH infusion.</description>
    <arm_group_label>PGX-ODSH-2013-AML-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed, previously untreated acute myeloid leukemia. Acute promyelocytic
             leukemia and acute megakaryoblastic leukemia subtypes are excluded

          -  No prior chemotherapy for acute myeloid leukemia; however, prior hydroxyurea to
             control white blood cell count is allowed

          -  Age: ≥18

          -  Eastern Cooperative Oncology Group (ECOG) Performance status 0-2

          -  Cardiac ejection fraction ≥ 50% (echocardiography or Multi-Gated Acquisition Scan
             [MUGA])

          -  Adequate hepatic and renal function (aspartate aminotransferase [AST], alanine
             aminotransferase [ALT], bilirubin and creatinine &lt; 2.5 x upper normal limit).

          -  Able to provide informed consent and have signed an approved consent form that
             conforms to federal and institutional guidelines.

        Exclusion Criteria:

          -  Patients with acute promyelocytic leukemia

          -  Patients with acute megakaryoblastic leukemia

          -  Patients with Central Nervous System (CNS) leukemia

          -  Presence of uncontrolled bleeding

          -  Presence of significant active infection that is uncontrolled as judged by the
             investigator

          -  History of severe congestive heart failure or other cardiac disease that
             contraindicates the use of anthracyclines, including idarubicin

          -  Pre-existing liver disease

          -  Renal insufficiency, which, in the opinion of the investigator, might adversely affect
             schedule and dose of therapy with cytarabine as well as management of tumor lysis
             syndrome. Patients with creatinine levels ≥2 mg/dl are not eligible

          -  Use of recreational drugs or history of drug addiction, within the prior 6 months

          -  Known history of positive hepatitis B surface antigens or hepatitis C virus (HCV)
             antibodies

          -  Known history of positive test for Human Immunodeficiency Virus (HIV) antibodies

          -  Psychiatric or neurologic conditions that could compromise patient safety or
             compliance, or interfere with the ability to give proper informed consent

          -  History of other active malignant disease within 5 years, other than cured basal cell
             carcinoma of the skin, cured in situ carcinoma of the cervix, or localized prostate
             cancer that has received definitive therapy. Such prostate cancer patients who are
             receiving hormonal therapy are eligible

          -  Presence of disseminated intravascular coagulation, as confirmed by laboratory studies
             demonstrating evidence of both increased thrombin generation (decreased fibrinogen,
             prolonged Prothrombin Time [PT] and Partial Thromboplastin Time [aPTT]) as well as
             increased fibrinolysis (elevated D-dimer level)

          -  Patients receiving any form of anticoagulant therapy

          -  Presence of a known bleeding disorder or coagulation abnormality

          -  Treatment with any other investigational agent within 7 days prior to study entry. All
             prior toxicities should have resolved to no greater than Grade 1 (with the exception
             of alopecia)

          -  Pregnant or breast-feeding patients

          -  Patient with childbearing potential not using adequate contraception

          -  Any condition that requires maintenance of platelet counts at 50,000/μL or higher.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Marcus, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cantex Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Shami, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah Huntsman Cancer Institute &amp; DSMB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgia Regents University Augusta - Div. of Hematology/Oncology - BMT</name>
      <address>
        <city>Agusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Huntsman Cancer Institute - Div. of Hematology &amp; Hematologic Malignncies</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Greer JP, Baer MR, Kinney MC. Acute Myelogenous Leukemia in Adults. In Wintrobe's Clinical Hematology. Lee GR et al ed. Williams and Wilkins, Baltimore, 2098-2142, 2004.</citation>
  </reference>
  <reference>
    <citation>Stroncek DF, Rebulla P. Platelet transfusions. Lancet. 2007 Aug 4;370(9585):427-38. Review.</citation>
    <PMID>17679020</PMID>
  </reference>
  <reference>
    <citation>Kuter DJ. What is the potential for thrombopoietic agents in acute leukemia? Best Pract Res Clin Haematol. 2011 Dec;24(4):553-8. doi: 10.1016/j.beha.2011.09.002. Epub 2011 Nov 4. Review.</citation>
    <PMID>22127320</PMID>
  </reference>
  <reference>
    <citation>Trafalis DT, Poulakidas E, Kapsimali V, Tsigris C, Papanicolaou X, Harhalakis N, Nikiforakis E, Mentzikof-Mitsouli C. Platelet production and related pathophysiology in acute myelogenous leukemia at first diagnosis: prognostic implications. Oncol Rep. 2008 Apr;19(4):1021-6.</citation>
    <PMID>18357391</PMID>
  </reference>
  <reference>
    <citation>Stasi R, Bosworth J, Rhodes E, Shannon MS, Willis F, Gordon-Smith EC. Thrombopoietic agents. Blood Rev. 2010 Jul-Sep;24(4-5):179-90. doi: 10.1016/j.blre.2010.04.002. Epub 2010 May 20. Review.</citation>
    <PMID>20493600</PMID>
  </reference>
  <reference>
    <citation>Majka M, Janowska-Wieczorek A, Ratajczak J, Kowalska MA, Vilaire G, Pan ZK, Honczarenko M, Marquez LA, Poncz M, Ratajczak MZ. Stromal-derived factor 1 and thrombopoietin regulate distinct aspects of human megakaryopoiesis. Blood. 2000 Dec 15;96(13):4142-51.</citation>
    <PMID>11110685</PMID>
  </reference>
  <reference>
    <citation>Lambert MP, Rauova L, Bailey M, Sola-Visner MC, Kowalska MA, Poncz M. Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. Blood. 2007 Aug 15;110(4):1153-60. Epub 2007 May 10.</citation>
    <PMID>17495129</PMID>
  </reference>
  <reference>
    <citation>Lambert MP, Reznikov A, Grubbs A, Nguyen Y, Xiao L, Aplenc R, Rauova L, Poncz M. Platelet factor 4 platelet levels are inversely correlated with steady-state platelet counts and with platelet transfusion needs in pediatric leukemia patients. J Thromb Haemost. 2012 Jul;10(7):1442-6. doi: 10.1111/j.1538-7836.2012.04767.x.</citation>
    <PMID>22564375</PMID>
  </reference>
  <reference>
    <citation>Lambert MP, Xiao L, Nguyen Y, Kowalska MA, Poncz M. The role of platelet factor 4 in radiation-induced thrombocytopenia. Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1533-40. doi: 10.1016/j.ijrobp.2011.03.039.</citation>
    <PMID>21740995</PMID>
  </reference>
  <reference>
    <citation>Joglekar MV, Quintana Diez PM, Marcus S, Qi R, Espinasse B, Wiesner MR, Pempe E, Liu J, Monroe DM, Arepally GM. Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH). Thromb Haemost. 2012 Apr;107(4):717-25. doi: 10.1160/TH11-11-0795. Epub 2012 Feb 8.</citation>
    <PMID>22318669</PMID>
  </reference>
  <reference>
    <citation>Lambert MP, Sharma SS, Xiao L, Marcus S et al. 2-O, 3-O-Desulfated Heparin (ODSH) Mitigates Chemotherapy-Induced Thrombocytopenia (CIT) by Blocking the Negative Paracrine Effect of Platelet Factor 4 (PF4) On Megakaryopoiesis. Proceedings of the 54th Annual Meeting of the American Society of Hematology. Abstract 386, 2012.</citation>
  </reference>
  <reference>
    <citation>Yang L, Yu Y, Kang R, Yang M, Xie M, Wang Z, Tang D, Zhao M, Liu L, Zhang H, Cao L. Up-regulated autophagy by endogenous high mobility group box-1 promotes chemoresistance in leukemia cells. Leuk Lymphoma. 2012 Feb;53(2):315-22. doi: 10.3109/10428194.2011.616962. Epub 2011 Nov 15.</citation>
    <PMID>21864037</PMID>
  </reference>
  <reference>
    <citation>Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, Loughran P, Bierhaus A, Lotze MT, Zeh HJ. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ. 2010 Apr;17(4):666-76. doi: 10.1038/cdd.2009.149. Epub 2009 Oct 16.</citation>
    <PMID>19834494</PMID>
  </reference>
  <reference>
    <citation>Rao NV, Argyle B, Xu X, Reynolds PR, Walenga JM, Prechel M, Prestwich GD, MacArthur RB, Walters BB, Hoidal JR, Kennedy TP. Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands. Am J Physiol Cell Physiol. 2010 Jul;299(1):C97-110. doi: 10.1152/ajpcell.00009.2010. Epub 2010 Apr 7.</citation>
    <PMID>20375277</PMID>
  </reference>
  <reference>
    <citation>Abe R, Shimizu T, Sugawara H, Watanabe H, Nakamura H, Choei H, Sasaki N, Yamagishi S, Takeuchi M, Shimizu H. Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol. 2004 Feb;122(2):461-7.</citation>
    <PMID>15009731</PMID>
  </reference>
  <reference>
    <citation>Logsdon CD, Fuentes MK, Huang EH, Arumugam T. RAGE and RAGE ligands in cancer. Curr Mol Med. 2007 Dec;7(8):777-89. Review.</citation>
    <PMID>18331236</PMID>
  </reference>
  <reference>
    <citation>Krauel K, Hackbarth C, Fürll B, Greinacher A. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood. 2012 Feb 2;119(5):1248-55. doi: 10.1182/blood-2011-05-353391. Epub 2011 Nov 2.</citation>
    <PMID>22049520</PMID>
  </reference>
  <reference>
    <citation>Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011 Dec 1;29(34):4548-54. doi: 10.1200/JCO.2011.36.5742. Epub 2011 Oct 3.</citation>
    <PMID>21969517</PMID>
  </reference>
  <reference>
    <citation>Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, Lotze MT. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res. 2007 May 15;13(10):2836-48. Review.</citation>
    <PMID>17504981</PMID>
  </reference>
  <reference>
    <citation>Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010;28:367-88. doi: 10.1146/annurev.immunol.021908.132603. Review.</citation>
    <PMID>20192808</PMID>
  </reference>
  <reference>
    <citation>Takada M, Hirata K, Ajiki T, Suzuki Y, Kuroda Y. Expression of receptor for advanced glycation end products (RAGE) and MMP-9 in human pancreatic cancer cells. Hepatogastroenterology. 2004 Jul-Aug;51(58):928-30.</citation>
    <PMID>15239215</PMID>
  </reference>
  <reference>
    <citation>Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000 May 18;405(6784):354-60.</citation>
    <PMID>10830965</PMID>
  </reference>
  <reference>
    <citation>Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE, Benschop R, Sparvero LJ, Amoscato AA, Tracey KJ, Zeh HJ, Lotze MT. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene. 2010 Sep 23;29(38):5299-310. doi: 10.1038/onc.2010.261. Epub 2010 Jul 12.</citation>
    <PMID>20622903</PMID>
  </reference>
  <reference>
    <citation>Tang D, Kang R, Livesey KM, Cheh CW, Farkas A, Loughran P, Hoppe G, Bianchi ME, Tracey KJ, Zeh HJ 3rd, Lotze MT. Endogenous HMGB1 regulates autophagy. J Cell Biol. 2010 Sep 6;190(5):881-92. doi: 10.1083/jcb.200911078.</citation>
    <PMID>20819940</PMID>
  </reference>
  <reference>
    <citation>Tang D, Loze MT, Zeh HJ, Kang R. The redox protein HMGB1 regulates cell death and survival in cancer treatment. Autophagy. 2010 Nov;6(8):1181-3. doi: 10.4161/auto.6.8.13367.</citation>
    <PMID>20861675</PMID>
  </reference>
  <reference>
    <citation>Kang R, Tang D, Loze MT, Zeh HJ. Apoptosis to autophagy switch triggered by the MHC class III-encoded receptor for advanced glycation endproducts (RAGE). Autophagy. 2011 Jan;7(1):91-3. doi: 10.1038/cdd.2009.149. Epub 2011 Jan 1.</citation>
    <PMID>20978368</PMID>
  </reference>
  <reference>
    <citation>Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003 Dec 15;21(24):4642-9. Erratum in: J Clin Oncol. 2004 Feb 1;22(3):576. LoCocco, Francesco [corrected to Lo-Coco, Francesco].</citation>
    <PMID>14673054</PMID>
  </reference>
  <reference>
    <citation>Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26;404-413, 1934.</citation>
  </reference>
  <reference>
    <citation>Harrill AH, Roach J, Fier I, Eaddy JS, Kurtz CL, Antoine DJ, Spencer DM, Kishimoto TK, Pisetsky DS, Park BK, Watkins PB. The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. Clin Pharmacol Ther. 2012 Aug;92(2):214-20. doi: 10.1038/clpt.2012.40. Epub 2012 Jun 27.</citation>
    <PMID>22739141</PMID>
  </reference>
  <reference>
    <citation>Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y, Xie M, Yin X, Livesey KM, Lotze MT, Tang D, Cao L. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia. 2011 Jan;25(1):23-31. doi: 10.1038/leu.2010.225. Epub 2010 Oct 7.</citation>
    <PMID>20927132</PMID>
  </reference>
  <reference>
    <citation>Tang D, Kang R, Zeh HJ 3rd, Lotze MT. High-mobility group box 1 and cancer. Biochim Biophys Acta. 2010 Jan-Feb;1799(1-2):131-40. doi: 10.1016/j.bbagrm.2009.11.014. Review.</citation>
    <PMID>20123075</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2014</study_first_submitted>
  <study_first_submitted_qc>February 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2014</study_first_posted>
  <last_update_submitted>February 12, 2015</last_update_submitted>
  <last_update_submitted_qc>February 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>ODSH</keyword>
  <keyword>ODSH-AML</keyword>
  <keyword>Cantex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>August 6, 2015</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>January 26, 2016</submitted>
    <returned>February 22, 2016</returned>
    <submitted>March 22, 2016</submitted>
    <returned>April 20, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

